Page last updated: 2024-12-07
n-(4-(2-benzoxazolyl)phenyl)maleimide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
This compound, also known as N-(4-(benzoxazol-2-yl)phenyl)maleimide, is a fluorescent probe with potential applications in various research fields. It exhibits high fluorescence quantum yield and sensitivity to environmental changes, making it suitable for sensing applications. The compound has been synthesized and characterized through various techniques, including nuclear magnetic resonance spectroscopy and mass spectrometry. Research on this compound focuses on its ability to detect specific analytes, such as metal ions and biomolecules, through fluorescence quenching or enhancement. The compound's fluorescence properties and its ability to interact with biomolecules make it a promising tool for biological imaging, disease diagnostics, and drug discovery. '
```
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 85555 |
| CHEMBL ID | 1722096 |
| SCHEMBL ID | 134975 |
| MeSH ID | M0116268 |
Synonyms (45)
| Synonym |
|---|
| n-(p-(2-benzoxazolyl)phenyl)maleimide |
| nsc-340300 |
| mls003116019 , |
| n-[p-(2-benzoxazolyl)phenyl]maleimide |
| 1h-pyrrole-2, 1-[4-(2-benzoxazolyl)phenyl]- |
| 16707-41-8 |
| maleimide, n-(p-2-benzoxazolylphenyl)- |
| nsc340300 |
| SR-01000639556-1 |
| smr001831577 |
| HMS1664P12 |
| AKOS002075163 |
| 1-[4-(1,3-benzoxazol-2-yl)phenyl]pyrrole-2,5-dione |
| unii-kf3p4v0po3 |
| kf3p4v0po3 , |
| 1h-pyrrole-2,5-dione, 1-(4-(2-benzoxazolyl)phenyl)- |
| n-(4-(2-benzoxazolyl)phenyl)maleimide |
| nsc 340300 |
| CCG-50157 |
| 1h-pyrrole-2,5-dione, 1-[4-(2-benzoxazolyl)phenyl]- |
| 1-(4-(benzo[d]oxazol-2-yl)phenyl)-1h-pyrrole-2,5-dione |
| SCHEMBL134975 |
| DTXSID6066103 |
| CHEMBL1722096 |
| cyto5d2 |
| 1-[4-(2-benzoxazolyl)phenyl]-1h-pyrrole-2,5-dione |
| n-[4-[2-benzoxazoyl]phenyl]maleimide |
| BGGCPIFVRJFAKF-UHFFFAOYSA-N |
| 1-[4-(1,3-benzoxazol-2-yl)phenyl]-1h-pyrrole-2,5-dione # |
| n-[p-(2-benzoxazolyl)phenyl]-maleimide |
| 2-(4-maleimidophenyl)benzoxazole |
| n-[4-(2-benzoxazolyl)phenyl]maleimide, aldrichcpr |
| mfcd00047253 |
| c17h10n2o3 |
| A882283 |
| n-[p-(2-benzoxazolyl)-phenyl]maleimide |
| n-[4-(2-benzoxazolyl)phenyl]maleimide |
| FT-0758821 |
| DS-15084 |
| 1-(4-(2-benzoxazolyl)phenyl)-1h-pyrrole-2,5-dione |
| n-(4-(benzoxazol-2-yl)phenyl)maleimide |
| Y13493 |
| 1-[4-(benzoxazol-2-yl)phenyl]-1h-pyrrole-2,5-dione;1-(4-(benzo[d]oxazol-2-yl)phenyl)-1h-pyrrole-2,5-dione |
| CS-0155910 |
| SY101943 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (10)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Nrf2 | Homo sapiens (human) | Potency | 15.8489 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.7358 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 14.1254 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 11.2202 | 0.2239 | 11.2451 | 35.4813 | AID624173; AID720584 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 100.0000 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 8.4368 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
| Vpr | Human immunodeficiency virus 1 | Potency | 6.3096 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 4.4668 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 (µMol) | 57.5333 | 0.8890 | 21.0286 | 71.5000 | AID504765; AID540252; AID540269 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 (µMol) | 80.0000 | 8.8700 | 12.8518 | 17.8000 | AID504792 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (77)
Molecular Functions (26)
Ceullar Components (22)
Bioassays (15)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.39) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||